Glycogen synthase kinase 3β in tumorigenesis and oncotherapy (Review)
- Authors:
- Rui He
- Suya Du
- Tiantian Lei
- Xiaofang Xie
- Yi Wang
-
Affiliations: Department of Union, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, P.R. China, Department of Clinical Pharmacy, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610041, P.R. China, Department of Pharmacy, Chongqing Health Center for Women and Children, Chongqing 400013, P.R. China, Department of Medicine, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610041, P.R. China, Personalized Drug Therapy Key Laboratory of Sichuan Province, Department of Pharmacy, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610041, P.R. China - Published online on: October 20, 2020 https://doi.org/10.3892/or.2020.7817
- Pages: 2373-2385
-
Copyright: © He et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
 |
 |
|
Grimes CA and Jope RS: The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol. 65:391–426. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Doble BW and Woodgett JR: GSK-3: Tricks of the trade for a multi-tasking kinase. J Cell Sci. 116:1175–1186. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Embi N, Rylatt DB and Cohen P: Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem. 107:519–527. 1980. View Article : Google Scholar : PubMed/NCBI | |
|
Woodgett JR: Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J. 9:2431–2438. 1990. View Article : Google Scholar : PubMed/NCBI | |
|
Thotala DK and Yazlovitskaya EM: GSK3B (glycogen synthase kinase 3 beta). Atlas Genet Cytogenet Oncol Haematol. 15:7–10. 2011. | |
|
Jope RS and Johnson GV: The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci. 29:95–102. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Fang X, Yu SX, Lu Y, Bast RC Jr, Woodgett JR and Mills GB: Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci USA. 97:11960–11965. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Cross DA, Alessi DR, Cohen P, Andjelkovich M and Hemmings BA: Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 378:785–789. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Summers SA, Kao AW, Kohn AD, Backus GS, Roth RA, Pessin JE and Birnbaum MJ: The role of glycogen synthase kinase 3beta in insulin-stimulated glucose metabolism. J Biol Chem. 274:17934–17940. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Jacobs KM, Bhave SR, Ferraro DJ, Jaboin JJ, Hallahan DE and Thotala D: GSK-3β: A bifunctional role in cell death pathways. Int J Cell Biol. 2012:9307102012. View Article : Google Scholar : PubMed/NCBI | |
|
Amar S, Belmaker RH and Agam G: The possible involvement of glycogen synthase kinase-3 (GSK-3) in diabetes, cancer and central nervous system diseases. Curr Pharm Des. 17:2264–2277. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Jope RS, Yuskaitis CJ and Beurel E: Glycogen synthase kinase-3 (GSK3): Inflammation, diseases, and therapeutics. Neurochem Res. 32:577–595. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Luo J: The role of GSK3beta in the development of the central nervous system. Front Biol (Beijing). 7:212–220. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Luo J: Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. Cancer Lett. 273:194–200. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Chiara F and Rasola A: GSK-3 and mitochondria in cancer cells. Front Oncol. 3:162013. View Article : Google Scholar : PubMed/NCBI | |
|
Naito S, Bilim V, Yuuki K, Ugolkov A, Motoyama T, Nagaoka A, Kato T and Tomita Y: Glycogen synthase kinase-3beta: A prognostic marker and a potential therapeutic target in human bladder cancer. Clin Cancer Res. 16:5124–5132. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Tang QL, Xie XB, Wang J, Chen Q, Han AJ, Zou CY, Yin JQ, Liu DW, Liang Y, Zhao ZQ, et al: Glycogen synthase kinase-3β, NF-κB signaling, and tumorigenesis of human osteosarcoma. J Natl Cancer Inst. 104:749–763. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Majewska E and Szeliga M: AKT/GSK3β signaling in glioblastoma. Neurochem Res. 42:918–924. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Domoto T, Pyko IV, Furuta T, Miyashita K, Uehara M, Shimasaki T, Nakada M and Minamoto T: Glycogen synthase kinase-3β is a pivotal mediator of cancer invasion and resistance to therapy. Cancer Sci. 107:1363–1372. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kotliarova S, Pastorino S, Kovell LC, Kotliarov Y, Song H, Zhang W, Bailey R, Maric D, Zenklusen JC, Lee J and Fine HA: Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation. Cancer Res. 68:6643–6651. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Najib S and Sánchez-Margalet V: Homocysteine thiolactone inhibits insulin-stimulated DNA and protein synthesis: Possible role of mitogen-activated protein kinase (MAPK), glycogen synthase kinase-3 (GSK-3) and p70 S6K phosphorylation. J Mol Endocrinol. 34:119–126. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Eldar-Finkelman H, Seger R, Vandenheede JR and Krebs EG: Inactivation of glycogen synthase kinase-3 by epidermal growth factor is mediated by mitogen-activated protein kinase/p90 ribosomal protein S6 kinase signaling pathway in NIH/3T3 cells. J Biol Chem. 270:987–990. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Hartigan JA, Xiong WC and Johnson GV: Glycogen synthase kinase 3beta is tyrosine phosphorylated by PYK2. Biochem Biophys Res Commun. 284:485–489. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Hartigan JA and Johnson GV: Transient increases in intracellular calcium result in prolonged site-selective increases in Tau phosphorylation through a glycogen synthase kinase 3beta-dependent pathway. J Biol Chem. 274:21395–21401. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Takahashi-Yanaga F, Shiraishi F, Hirata M, Miwa Y, Morimoto S and Sasaguri T: Glycogen synthase kinase-3beta is tyrosine-phosphorylated by MEK1 in human skin fibroblasts. Biochem Biophys Res Commun. 316:411–415. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Bijur GN and Jope RS: Glycogen synthase kinase-3 beta is highly activated in nuclei and mitochondria. Neuroreport. 14:2415–2419. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Diehl JA, Cheng M, Roussel MF and Sherr CJ: Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 12:3499–3511. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Manoukian AS and Woodgett JR: Role of glycogen synthase kinase-3 in cancer: Regulation by Wnts and other signaling pathways. Adv Cancer Res. 84:203–229. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Valvezan AJ, Zhang F, Diehl JA and Klein PS: Adenomatous polyposis coli (APC) regulates multiple signaling pathways by enhancing glycogen synthase kinase-3 (GSK-3) activity. J Biol Chem. 287:3823–3832. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Peifer M and Polakis P: Wnt signaling in oncogenesis and embryogenesis-a look outside the nucleus. Science. 287:1606–1609. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Lustig B and Behrens J: The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol. 129:199–221. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Giles RH, van Es JH and Clevers H: Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta. 1653:1–24. 2003.PubMed/NCBI | |
|
Watcharasit P, Bijur GN, Zmijewski JW, Song L, Zmijewska A, Chen X, Johnson GV and Jope RS: Direct, activating interaction between glycogen synthase kinase-3beta and p53 after DNA damage. Proc Natl Acad Sci USA. 99:7951–7955. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Watcharasit P, Bijur GN, Song L, Zhu J, Chen X and Jope RS: Glycogen synthase kinase-3beta (GSK3beta) binds to and promotes the actions of p53. J Biol Chem. 278:48872–48879. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Lang UE, Kocabayoglu P, Cheng GZ, Ghiassi-Nejad Z, Muñoz U, Vetter D, Eckstein DA, Hannivoort RA, Walsh MJ and Friedman SL: GSK3β phosphorylation of the KLF6 tumor suppressor promotes its transactivation of p21. Oncogene. 32:4557–4564. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Lin J, Song T, Li C and Mao W: GSK-3β in DNA repair, apoptosis, and resistance of chemotherapy, radiotherapy of cancer. Biochim Biophys Acta Mol Cell Res. 1867:1186592020. View Article : Google Scholar : PubMed/NCBI | |
|
Wang L, Lin HK, Hu YC, Xie S, Yang L and Chang C: Suppression of androgen receptor-mediated transactivation and cell growth by the glycogen synthase kinase 3 beta in prostate cells. J Biol Chem. 279:32444–32452. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Shakoori A, Ougolkov A, Yu ZW, Zhang B, Modarressi MH, Billadeau DD, Mai M, Takahashi Y and Minamoto T: Deregulated GSK3beta activity in colorectal cancer: Its association with tumor cell survival and proliferation. Biochem Biophys Res Commun. 334:1365–1373. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Takahashi-Yanaga F and Sasaguri T: GSK-3beta regulates cyclin D1 expression: A new target for chemotherapy. Cell Signal. 20:581–589. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Verras M and Sun Z: Roles and regulation of Wnt signaling and beta-catenin in prostate cancer. Cancer Lett. 237:22–32. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Sharma M, Chuang WW and Sun Z: Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation. J Biol Chem. 277:30935–30941. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Quintayo MA, Munro AF, Thomas J, Kunkler IH, Jack W, Kerr GR, Dixon JM, Chetty U and Bartlett JM: GSK3β and cyclin D1 expression predicts outcome in early breast cancer patients. Breast Cancer Res Treat. 136:161–168. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Lam JB, Lam KS, Liu J, Lam MC, Hoo RL, Wu D, Cooper GJ and Xu A: Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. Cancer Res. 66:11462–11470. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Baral R, Patnaik S and Das BR: Co-overexpression of p53 and c-myc proteins linked with advanced stages of betel- and tobacco-related oral squamous cell carcinomas from eastern India. Eur J Oral Sci. 106:907–913. 2010. View Article : Google Scholar | |
|
de Sousa SO, Mesquita RA, Pinto DS Jr and Gutkind S: Immunolocalization of c-Fos and c-Jun in human oral mucosa and in oral squamous cell carcinoma. J Oral Pathol Med. 31:78–81. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Franz M, Spiegel K, Umbreit C, Richter P, Codina-Canet C, Berndt A, Altendorf-Hofmann A, Koscielny S, Hyckel P, Kosmehl H, et al: Expression of Snail is associated with myofibroblast phenotype development in oral squamous cell carcinoma. Histochem Cell Biol. 131:651–660. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Iwai S, Katagiri W, Kong C, Amekawa S, Nakazawa M and Yura Y: Mutations of the APC, beta-catenin, and axin 1 genes and cytoplasmic accumulation of beta-catenin in oral squamous cell carcinoma. J Cancer Res Clin Oncol. 131:773–782. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Buss H, Dörrie A, Schmitz ML, Frank R, Livingstone M, Resch K and Kracht M: Phosphorylation of serine 468 by GSK-3beta negatively regulates basal p65 NF-kappaB activity. J Biol Chem. 279:49571–49574. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Goto H, Kawano K, Kobayashi I, Sakai H and Yanagisawa S: Expression of cyclin D1 and GSK-3beta and their predictive value of prognosis in squamous cell carcinomas of the tongue. Oral Oncol. 38:549–556. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Mishra A, Bharti AC, Saluja D and Das BC: Transactivation and expression patterns of Jun and Fos/AP-1 super-family proteins in human oral cancer. Int J Cancer. 126:819–829. 2010.PubMed/NCBI | |
|
Mishra R: Glycogen synthase kinase 3 beta: Can it be a target for oral cancer. Mol Cancer. 9:1442010. View Article : Google Scholar : PubMed/NCBI | |
|
Bauer K, Dowejko A, Bosserhoff AK, Reichert TE and Bauer RJ: P-cadherin induces an epithelial-like phenotype in oral squamous cell carcinoma by GSK-3beta-mediated Snail phosphorylation. Carcinogenesis. 30:1781–1788. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Kornberg LJ: Focal adhesion kinase expression in oral cancers. Head Neck. 20:634–639. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Ko BS, Chang TC, Chen CH, Liu CC, Kuo CC, Hsu C, Shen YC, Shen TL, Golubovskaya VM, Chang CC, et al: Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B. Life Sci. 86:199–206. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Takeuchi H, Taoka R, Mmeje CO, Jinesh GG, Safe S and Kamat AM: CDODA-Me decreases specificity protein transcription factors and induces apoptosis in bladder cancer cells through induction of reactive oxygen species. Urol Oncol. 34:337.e11–e18. 2016. View Article : Google Scholar | |
|
Miller WP, Toro AL, Barber AJ and Dennis MD: REDD1 Activates a ROS-generating feedback loop in the retina of diabetic mice. Invest Ophthalmol Vis Sci. 60:2369–2379. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Deng S, Dai G, Chen S, Nie Z, Zhou J, Fang H and Peng H: Dexamethasone induces osteoblast apoptosis through ROS-PI3K/AKT/GSK3β signaling pathway. Biomed Pharmacother. 110:602–608. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Ziober BL, Silverman SS Jr and Kramer RH: Adhesive mechanisms regulating invasion and metastasis in oral cancer. Crit Rev Oral Biol Med. 12:499–510. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Erdem NF, Carlson ER, Gerard DA and Ichiki AT: Characterization of 3 oral squamous cell carcinoma cell lines with different invasion and/or metastatic potentials. J Oral Maxillofac Surg. 65:1725–1733. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao J and Liao K: Expression of macrophage migration inhibitory factor in esophageal squamous cell carcinoma and normal esophageal tissue. Acta Acad Med Mil Tertiae. 29:740–742. 2008. | |
|
Liu RM, Sun DN, Jiao YL, Wang P, Zhang J, Wang M, Ma J, Sun M, Gu BL, Chen P, et al: Macrophage migration inhibitory factor promotes tumor aggressiveness of esophageal squamous cell carcinoma via activation of Akt and inactivation of GSK3β. Cancer Lett. 412:289–296. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Wang H, Wang HS, Zhou BH, Li CL, Zhang F, Wang XF, Zhang G, Bu XZ, Cai SH and Du J: Epithelial-mesenchymal transition (EMT) induced by TNF-α requires AKT/GSK-3β-mediated stabilization of snail in colorectal cancer. PLoS One. 8:e566642013. View Article : Google Scholar : PubMed/NCBI | |
|
Kao SH, Wang WL, Chen CY, Chang YL, Wu YY, Wang YT, Wang SP, Nesvizhskii AI, Chen YJ, Hong TM and Yang PC: GSK3β controls epithelial-mesenchymal transition and tumor metastasis by CHIP-mediated degradation of Slug. Oncogene. 33:3172–3182. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Shakoori A, Mai W, Miyashita K, Yasumoto K, Takahashi Y, Ooi A, Kawakami K and Minamoto T: Inhibition of GSK-3 beta activity attenuates proliferation of human colon cancer cells in rodents. Cancer Sci. 98:1388–1393. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Vidri RJ and Fitzgerald TL: GSK-3: An important kinase in colon and pancreatic cancers. Biochim Biophys Acta Mol Cell Res. 1867:1186262020. View Article : Google Scholar : PubMed/NCBI | |
|
Huang W, Chang HY, Fei T, Wu H and Chen YG: GSK3 beta mediates suppression of cyclin D2 expression by tumor suppressor PTEN. Oncogene. 26:2471–2482. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Ban JO, Oh JH, Son SM, Won D, Song HS, Han SB, Moon DC, Kang KW, Song MJ and Hong JT: Troglitazone, a PPAR agonist, inhibits human prostate cancer cell growth through inactivation of NFΚB via suppression of GSK-3β expression. Cancer Biol Ther. 12:288–296. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Ban JO, Kwak DH, Oh JH, Park EJ, Cho MC, Song HS, Song MJ, Han SB, Moon DC, Kang KW and Hong JT: Suppression of NF-kappaB and GSK-3beta is involved in colon cancer cell growth inhibition by the PPAR agonist troglitazone. Chem Biol Interact. 188:75–85. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Ghosh JC and Altieri DC: Activation of p53-dependent apoptosis by acute ablation of glycogen synthase kinase-3beta in colorectal cancer cells. Clin Cancer Res. 11:4580–4588. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Perse M and Cerar A: Morphological and molecular alterations in 1,2 dimethylhydrazine and azoxymethane induced colon carcinogenesis in rats. J Biomed Biotechnol. 2011:4739642011. View Article : Google Scholar : PubMed/NCBI | |
|
Ougolkov AV, Fernandez-Zapico ME, Bilim VN, Smyrk TC, Chari ST and Billadeau DD: Aberrant nuclear accumulation of glycogen synthase kinase-3beta in human pancreatic cancer: Association with kinase activity and tumor dedifferentiation. Clin Cancer Res. 12:5074–5081. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou W, Wang L, Gou SM, Wang TL, Zhang M, Liu T and Wang CY: ShRNA silencing glycogen synthase kinase-3 beta inhibits tumor growth and angiogenesis in pancreatic cancer. Cancer Lett. 316:178–186. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Cao Q, Lu X and Feng YJ: Glycogen synthase kinase-3beta positively regulates the proliferation of human ovarian cancer cells. Cell Res. 16:671–677. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Miyashita K, Kawakami K, Nakada M, Mai W, Shakoori A, Fujisawa H, Hayashi Y, Hamada J and Minamoto T: Potential therapeutic effect of glycogen synthase kinase 3beta inhibition against human glioblastoma. Clin Cancer Res. 15:887–897. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Yang Y, Lei T, Du S, Tong R, Wang H, Yang J, Huang J, Sun M, Wang Y and Dong Z: Nuclear GSK3β induces DNA double-strand break repair by phosphorylating 53BP1 in glioblastoma. Int J Oncol. 52:709–720. 2018.PubMed/NCBI | |
|
Nishimura H, Nakamura O, Yamagami Y, Mori M, Horie R, Fukuoka N and Yamamoto T: GSK-3 inhibitor inhibits cell proliferation and induces apoptosis in human osteosarcoma cells. Oncol Rep. 35:2348–2354. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kerkela R, Kockeritz L, Macaulay K, Zhou J, Doble BW, Beahm C, Greytak S, Woulfe K, Trivedi CM, Woodgett JR, et al: Deletion of GSK-3beta in mice leads to hypertrophic cardiomyopathy secondary to cardiomyoblast hyperproliferation. J Clin Invest. 118:3609–3618. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O and Woodgett JR: Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature. 406:86–90. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
McManus EJ, Sakamoto K, Armit LJ, Ronaldson L, Shpiro N, Marquez R and Alessi DR: Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis. EMBO J. 24:1571–1583. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Z, Smith KS, Murphy M, Piloto O, Somervaille TC and Cleary ML: Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. Nature. 455:1205–1209. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Vigneron F, Dos Santos P, Lemoine S, Bonnet M, Tariosse L, Couffinhal T, Duplaà C and Jaspard-Vinassa B: GSK-3β at the crossroads in the signalling of heart preconditioning: Implication of mTOR and Wnt pathways. Cardiovasc Res. 90:49–56. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Fu Y, Hu D, Qiu J, Xie X, Ye F and Lu WG: Overexpression of glycogen synthase kinase-3 in ovarian carcinoma cells with acquired paclitaxel resistance. Int J Gynecol Cancer. 21:439–444. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Grassilli E, Narloch R, Federzoni E, Ianzano L, Pisano F, Giovannoni R, Romano G, Masiero L, Leone BE, Bonin S, et al: Inhibition of GSK3B bypass drug resistance of p53-null colon carcinomas by enabling necroptosis in response to chemotherapy. Clin Cancer Res. 19:3820–3831. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Kawazoe H, Bilim VN, Ugolkov AV, Yuuki K, Naito S, Nagaoka A, Kato T and Tomita Y: GSK-3 inhibition in vitro and in vivo enhances antitumor effect of sorafenib in renal cell carcinoma (RCC). Biochem Biophys Res Commun. 423:490–495. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Cai G, Wang J, Xin X, Ke Z and Luo J: Phosphorylation of glycogen synthase kinase-3 beta at serine 9 confers cisplatin resistance in ovarian cancer cells. Int J Oncol. 31:657–662. 2007.PubMed/NCBI | |
|
Beurel E, Kornprobst M, Blivet-Van Eggelpoël MJ, Cadoret A, Capeau J and Desbois-Mouthon C: GSK-3beta reactivation with LY294002 sensitizes hepatoma cells to chemotherapy-induced apoptosis. Int J Oncol. 27:215–222. 2005.PubMed/NCBI | |
|
Alao JP, Stavropoulou AV, Lam WF and Coombes RC: Role of glycogen synthase kinase 3 beta (GSK3beta) in mediating the cytotoxic effects of the histone deacetylase inhibitor trichostatin A (TSA) in MCF-7 breast cancer cells. Mol Cancer. 5:402006. View Article : Google Scholar : PubMed/NCBI | |
|
Pyko IV, Nakada M, Sabit H, Teng L, Furuyama N, Hayashi Y, Kawakami K, Minamoto T, Fedulau AS and Hamada J: Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling. Carcinogenesis. 34:2206–2217. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Shimasaki T, Ishigaki Y, Nakamura Y, Takata T, Nakaya N, Nakajima H, Sato I, Zhao X, Kitano A, Kawakami K, et al: Glycogen synthase kinase 3β inhibition sensitizes pancreatic cancer cells to gemcitabine. J Gastroenterol. 47:321–333. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kitano A, Shimasaki T, Chikano Y, Nakada M, Hirose M, Higashi T, Ishigaki Y, Endo Y, Takino T, Sato H, et al: Aberrant glycogen synthase kinase 3β is involved in pancreatic cancer cell invasion and resistance to therapy. PLoS One. 8:e552892013. View Article : Google Scholar : PubMed/NCBI | |
|
Maqbool M and Hoda N: GSK3 inhibitors in the therapeutic development of diabetes, cancer and neurodegeneration: Past, present and future. Curr Pharm Des. 23:4332–4350. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Bowden CL: Efficacy of lithium in mania and maintenance therapy of bipolar disorder. J Clin Psychiatry. 61 (Suppl 9):S35–S40. 2000. | |
|
Del Grande C, Muti M, Musetti L, Pergentini I, Corsi M, Turri M, Soldani I, Corsini GU and Dell'Osso L: Long-term treatment of bipolar disorder: How should we use lithium salts? Riv Psichiatr. 47:515–526. 2012.(In Italian). PubMed/NCBI | |
|
Clément-Lacroix P, Ai M, Morvan F, Roman-Roman S, Vayssière B, Belleville C, Estrera K, Warman ML, Baron R and Rawadi G: Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. Proc Natl Acad Sci USA. 102:17406–17411. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Stump RJ, Lovicu FJ, Ang SL, Pandey SK and McAvoy JW: Lithium stabilizes the polarized lens epithelial phenotype and inhibits proliferation, migration, and epithelial mesenchymal transition. J Pathol. 210:249–257. 2010. View Article : Google Scholar | |
|
Sun A, Shanmugam I, Song J, Terranova PF, Thrasher JB and Li B: Lithium suppresses cell proliferation by interrupting E2F-DNA interaction and subsequently reducing S-phase gene expression in prostate cancer. Prostate. 67:976–988. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Song L, Zhou T and Jope RS: Lithium facilitates apoptotic signaling induced by activation of the Fas death domain-containing receptor. BMC Neurosci. 5:202004. View Article : Google Scholar : PubMed/NCBI | |
|
Karlovic D, Jakopec S, Dubravcic K, Batinic D, Buljan D and Osmak M: Lithium increases expression of p21 WAF/Cip1 and survivin in human glioblastoma cells. Cell Biol Toxicol. 23:83–90. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Neel BD, Lopez J, Chabadel A and Gillet G: Lithium suppresses motility and invasivity of v-src-transformed cells by glutathione-dependent activation of phosphotyrosine phosphatases. Oncogene. 28:3246–3260. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Hilliard T, Muehlbauer A, Gaisina I, Gaisin A, Gallier F, Kozikowski A and Burdette J: Novel glycogen synthase kinase 3beta inhibitors induce apoptosis in ovarian cancer. Biol Reprod. 83 (Suppl 1):S6912010. View Article : Google Scholar | |
|
Rinnab L, Schütz SV, Diesch J, Schmid E, Küfer R, Hautmann RE, Spindler KD and Cronauer MV: Inhibition of glycogen synthase kinase-3 in androgen-responsive prostate cancer cell lines: Are GSK inhibitors therapeutically useful? Neoplasia. 10:624–634. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Schütz SV, Schrader AJ, Zengerling F, Genze F, Cronauer MV and Schrader M: Inhibition of glycogen synthase kinase-3β counteracts ligand-independent activity of the androgen receptor in castration resistant prostate cancer. PLoS One. 6:e253412011. View Article : Google Scholar : PubMed/NCBI | |
|
Marchand B, Tremblay I, Cagnol S and Boucher MJ: Inhibition of glycogen synthase kinase-3 activity triggers an apoptotic response in pancreatic cancer cells through JNK-dependent mechanisms. Carcinogenesis. 33:529–537. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Coghlan MP, Culbert AA, Cross DA, Corcoran SL, Yates JW, Pearce NJ, Rausch OL, Murphy GJ, Carter PS, Roxbee Cox L, et al: Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol. 7:793–803. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Beurel E, Blivet-Van Eggelpoel MJ, Kornprobst M, Moritz S, Delelo R, Paye F, Housset C and Desbois-Mouthon C: Glycogen synthase kinase-3 inhibitors augment TRAIL-induced apoptotic death in human hepatoma cells. Biochem Pharmacol. 77:54–65. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Piazza F, Manni S, Tubi LQ, Montini B, Pavan L, Colpo A, Gnoato M, Cabrelle A, Adami F, Zambello R, et al: Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death. BMC Cancer. 10:5262010. View Article : Google Scholar : PubMed/NCBI | |
|
Dickey A, Schleicher S, Leahy K, Hu R, Hallahan D and Thotala DK: GSK-3β inhibition promotes cell death, apoptosis, and in vivo tumor growth delay in neuroblastoma Neuro-2A cell line. J Neurooncol. 104:145–153. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu Q, Yang J, Han S, Liu J, Holzbeierlein J, Thrasher JB and Li B: Suppression of glycogen synthase kinase 3 activity reduces tumor growth of prostate cancer in vivo. Prostate. 71:835–845. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Yan P, Tang H, Chen X, Ji S, Jin W, Zhang J, Shen J, Deng H, Zhao X, Shen Q and Huang H: Tamoxifen attenuates dialysate-induced peritoneal fibrosis by inhibiting GSK-3β/β-catenin axis activation. Biosci Rep. 38:BSR201802402018. View Article : Google Scholar : PubMed/NCBI | |
|
Tang YY, Sheng SY, Lu CG, Zhang YQ, Zou JY, Lei YY, Gu Y and Hong H: Effects of glycogen synthase kinase-3β inhibitor TWS119 on proliferation and cytokine production of TILs from human lung cancer. J Immunother. 41:319–328. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Guzmán EA, Johnson JD, Linley PA, Gunasekera SE and Wright AE: A novel activity from an old compound: Manzamine A reduces the metastatic potential of AsPC-1 pancreatic cancer cells and sensitizes them to TRAIL-induced apoptosis. Invest New Drugs. 29:777–785. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Mamaghani S, Patel S and Hedley DW: Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy. BMC Cancer. 9:1322009. View Article : Google Scholar : PubMed/NCBI | |
|
Gaisina IN, Gallier F, Ougolkov AV, Kim KH, Kurome T, Guo S, Holzle D, Luchini DN, Blond SY, Billadeau DD and Kozikowski AP: From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells. J Med Chem. 52:1853–1863. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Kuroki H, Anraku T, Kazama A, Bilim V, Tasaki M, Schmitt D, Mazar AP, Giles FJ, Ugolkov A and Tomita Y: 9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer. Sci Rep. 9:199772019. View Article : Google Scholar : PubMed/NCBI | |
|
Anraku T, Kuroki H, Kazama A, Bilim V, Tasaki M, Schmitt D, Mazar A, Giles FJ, Ugolkov A and Tomita Y: Clinically relevant GSK3β inhibitor 9-ING-41 is active as a single agent and in combination with other antitumor therapies in human renal cancer. Int J Mol Med. 45:315–323. 2020.PubMed/NCBI | |
|
Ugolkov AV, Bondarenko GI, Dubrovskyi O, Berbegall AP, Navarro S, Noguera R, O'Halloran TV, Hendrix MJ, Giles FJ and Mazar AP: 9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma. Anticancer Drugs. 29:717–724. 2018.PubMed/NCBI | |
|
Karmali R, Chukkapalli V, Gordon LI, Borgia JA, Ugolkov A, Mazar AP and Giles FJ: GSK-3β inhibitor, 9-ING-41, reduces cell viability and halts proliferation of B-cell lymphoma cell lines as a single agent and in combination with novel agents. Oncotarget. 8:114924–114934. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ugolkov A, Gaisina I, Zhang JS, Billadeau DD, White K, Kozikowski A, Jain S, Cristofanilli M, Giles F, O'Halloran T, et al: GSK-3 inhibition overcomes chemoresistance in human breast cancer. Cancer Lett. 380:384–392. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Ugolkov A, Qiang W, Bondarenko G, Procissi D, Gaisina I, James CD, Chandler J, Kozikowski A, Gunosewoyo H, O'Halloran T, et al: Combination treatment with the GSK-3 Inhibitor 9-ING-41 and CCNU cures orthotopic chemoresistant glioblastoma in patient-derived xenograft models. Transl Oncol. 10:669–678. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Hilliard TS, Gaisina IN, Muehlbauer AG, Gaisin AM, Gallier F and Burdette JE: Glycogen synthase kinase 3β inhibitors induce apoptosis in ovarian cancer cells and inhibit in-vivo tumor growth. Anticancer Drugs. 22:978–985. 2011.PubMed/NCBI | |
|
Jeffers A, Qin W, Owens S, Koenig KB, Komatsu S, Giles FJ, Schmitt DM, Idell S and Tucker TA: Glycogen synthase kinase-3β inhibition with 9-ING-41 attenuates the progression of pulmonary fibrosis. Sci Rep. 9:189252019. View Article : Google Scholar : PubMed/NCBI | |
|
Gotschel F, Kern C, Lang S, Sparna T, Markmann C, Schwager J, McNelly S, von Weizsäcker F, Laufer S, Hecht A and Merfort I: Inhibition of GSK3 differentially modulates NF-kappaB, CREB, AP-1 and beta-catenin signaling in hepatocytes, but fails to promote TNF-alpha-induced apoptosis. Exp Cell Res. 314:1351–1366. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng Y, Pardo M, Armini RS, Martinez A, Mouhsine H, Zagury JF, Jope RS and Beurel E: Stress-induced neuroinflammation is mediated by GSK3-dependent TLR4 signaling that promotes susceptibility to depression-like behavior. Brain Behav Immun. 53:207–222. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Hoffmeister L, Diekmann M, Brand K and Huber R: GSK3: A kinase balancing promotion and resolution of inflammation. Cells. 9:8202020. View Article : Google Scholar | |
|
Teng L, Meng Q, Lu J, Xie J, Wang Z, Liu Y and Wang D: Liquiritin modulates ERK and AKT/GSK-3β-dependent pathways to protect against glutamate-induced cell damage in differentiated PC12 cells. Mol Med Rep. 10:818–824. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Gerhardt D, Bertola G, Dietrich F, Figueiró F, Zanotto-Filho A, Moreira Fonseca JC, Morrone FB, Barrios CH, Battastini AM and Salbego CG: Boldine induces cell cycle arrest and apoptosis in T24 human bladder cancer cell line via regulation of ERK, AKT, and GSK-3β. Urol Oncol. 32:36.e1–e9. 2014. View Article : Google Scholar | |
|
Kwon HJ, Kwon SJ, Lee H, Park HR, Choi GE, Kang SW, Kwon SW, Kim N, Lee SY, Ryu S, et al: NK cell function triggered by multiple activating receptors is negatively regulated by glycogen synthase kinase-3β. Cell Signal. 27:1731–1741. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Fionda C, Soriani A, Zingoni A, Santoni A and Cippitelli M: NKG2D and DNAM-1 ligands: Molecular targets for NK cell-mediated immunotherapeutic intervention in multiple myeloma. Biomed Res Int. 2015:1786982015. View Article : Google Scholar : PubMed/NCBI | |
|
Fionda C, Malgarini G, Soriani A, Zingoni A, Cecere F, Iannitto ML, Ricciardi MR, Federico V, Petrucci MT, Santoni A and Cippitelli M: Inhibition of glycogen synthase kinase-3 increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: Role of STAT3. J Immunol. 190:6662–6672. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Parameswaran R, Ramakrishnan P, Moreton SA, Xia Z, Hou Y, Lee DA, Gupta K, deLima M, Beck RC and Wald DN: Repression of GSK3 restores NK cell cytotoxicity in AML patients. Nat Commun. 7:111542016. View Article : Google Scholar : PubMed/NCBI | |
|
Cichocki F, Valamehr B, Bjordahl R, Zhang B, Rezner B, Rogers P, Gaidarova S, Moreno S, Tuininga K, Dougherty P, et al: GSK3 inhibition drives maturation of NK cells and enhances their antitumor activity. Cancer Res. 77:5664–5675. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ohteki T, Parsons M, Zakarian A, Jones RG, Nguyen LT, Woodgett JR and Ohashi PS: Negative regulation of T cell proliferation and interleukin 2 production by the serine threonine kinase GSK-3. J Exp Med. 192:99–104. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Taylor A and Rudd CE: Glycogen synthase kinase 3 inactivation compensates for the lack of CD28 in the priming of CD8+ cytotoxic T-cells: Implications for anti-PD-1 immunotherapy. Front Immunol. 8:16532017. View Article : Google Scholar : PubMed/NCBI | |
|
Taylor A, Harker JA, Chanthong K, Stevenson PG, Zuniga EI and Rudd CE: Glycogen synthase kinase 3 inactivation drives T-bet-mediated downregulation of Co-receptor PD-1 to enhance CD8(+) cytolytic T cell responses. Immunity. 44:274–286. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Taylor A, Rothstein D and Rudd CE: Small-molecule inhibition of PD-1 transcription is an effective alternative to antibody blockade in cancer therapy. Cancer Res. 78:706–717. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Rudd CE, Chanthong K and Taylor A: Small molecule inhibition of GSK-3 specifically inhibits the transcription of inhibitory Co-receptor LAG-3 for enhanced anti-tumor immunity. Cell Rep. 30:2075–2082.e4. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang JY, Zhao YL, Lv YP, Cheng P, Chen W, Duan M, Teng YS, Wang TT, Peng LS, Mao FY, et al: Modulation of CD8+ memory stem T cell activity and glycogen synthase kinase 3β inhibition enhances anti-tumoral immunity in gastric cancer. Oncoimmunology. 7:e14129002018. View Article : Google Scholar : PubMed/NCBI | |
|
Xia Y, Zhuo H, Lu Y, Deng L, Jiang R, Zhang L, Zhu Q, Pu L, Wang X and Lu L: Glycogen synthase kinase 3β inhibition promotes human iTreg differentiation and suppressive function. Immunol Res. 62:60–70. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Sengupta S, Katz SC, Sengupta S and Sampath P: Glycogen synthase kinase 3 inhibition lowers PD-1 expression, promotes long-term survival and memory generation in antigen-specific CAR-T cells. Cancer Lett. 433:131–139. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Takeuchi H, Tanaka M, Tanaka A, Tsunemi A and Yamamoto H: Predominance of M2-polarized macrophages in bladder cancer affects angiogenesis, tumor grade and invasiveness. Oncol Lett. 11:3403–3408. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wang G, Shi Y, Jiang X, Leak RK, Hu X, Wu Y, Pu H, Li WW, Tang B, Wang Y, et al: HDAC inhibition prevents white matter injury by modulating microglia/macrophage polarization through the GSK3β/PTEN/Akt axis. Proc Natl Acad Sci USA. 112:2853–2858. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Mazor M, Kawano Y, Zhu H, Waxman J and Kypta RM: Inhibition of glycogen synthase kinase-3 represses androgen receptor activity and prostate cancer cell growth. Oncogene. 23:7882–7892. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Goc A, Al-Husein B, Katsanevas K, Steinbach A, Lou U, Sabbineni H, DeRemer DL and Somanath PR: Targeting Src-mediated Tyr216 phosphorylation and activation of GSK-3 in prostate cancer cells inhibit prostate cancer progression in vitro and in vivo. Oncotarget. 5:775–787. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Yu XJ, Han QB, Wen ZS, Ma L, Gao J and Zhou GB: Gambogenic acid induces G1 arrest via GSK3β-dependent cyclin D1 degradation and triggers autophagy in lung cancer cells. Cancer Lett. 322:185–194. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kunnimalaiyaan S, Gamblin TC and Kunnimalaiyaan M: Glycogen synthase kinase-3 inhibitor AR-A014418 suppresses pancreatic cancer cell growth via inhibition of GSK-3-mediated Notch1 expression. HPB (Oxford). 17:770–776. 2015. View Article : Google Scholar : PubMed/NCBI |
